To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Inclusion Criteria: * Participants with hepatic impairment. * Participants eligible for Group 4 should be in good health. * Participants eligible for Groups 1 through 3 may have medical findings consistent with their degree of hepatic dysfunction. * Participants with abnormal findings considered not clinically significant by the investigator are eligible. * Body mass index within the range of 18.0 to 40.0 kg/m2 (inclusive) at screening. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Evidence of rapidly deteriorating hepatic function. * Participants with serum calcium and phosphorus levels over the upper limits of the institutional normal ranges. * History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including any of the following: * Participants who have a current, functioning organ transplant or have a scheduled organ transplant in the next 6 weeks from check-in. * History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer. * History of clinically significant gastrointestinal disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug. * Participants with severe ascites or an encephalopathy ≥ Grade 2. * Any major surgery within 4 weeks of screening. * Donation of blo…